Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
-
- JIAPAER Shabierjiang
- Department of Neurosurgery, Kanazawa University
-
- FURUTA Takuya
- Department of Pathology, Kurume University
-
- TANAKA Shingo
- Department of Neurosurgery, Kanazawa University
-
- KITABAYASHI Tomohiro
- Department of Neurosurgery, Kanazawa University
-
- NAKADA Mitsutoshi
- Department of Neurosurgery, Kanazawa University
この論文をさがす
説明
<p>Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality rate. Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patient’s post-operative survival but most cases eventually demonstrate resistance to TMZ. O6-methylguanine-DNA methyltransferase (MGMT) repairs the main cytotoxic lesion, as O6-methylguanine, generated by TMZ, can be the main mechanism of the drug resistance. In addition, mismatch repair and BER also contribute to TMZ resistance. TMZ treatment can induce self-protective autophagy, a mechanism by which tumor cells resist TMZ treatment. Emerging evidence also demonstrated that a small population of cells expressing stem cell markers, also identified as GBM stem cells (GSCs), contributes to drug resistance and tumor recurrence owing to their ability for self-renewal and invasion into neighboring tissue. Some molecules maintain stem cell properties. Other molecules or signaling pathways regulate stemness and influence MGMT activity, making these GCSs attractive therapeutic targets. Treatments targeting these molecules and pathways result in suppression of GSCs stemness and, in highly resistant cases, a decrease in MGMT activity. Recently, some novel therapeutic strategies, targeted molecules, immunotherapies, and microRNAs have provided new potential treatments for highly resistant GBM cases. In this review, we summarize the current knowledge of different resistance mechanisms, novel strategies for enhancing the effect of TMZ, and emerging therapeutic approaches to eliminate GSCs, all with the aim to produce a successful GBM treatment and discuss future directions for basic and clinical research to achieve this end.</p>
収録刊行物
-
- Neurologia medico-chirurgica
-
Neurologia medico-chirurgica 58 (10), 405-421, 2018
一般社団法人 日本脳神経外科学会
